InsiderDirector
Blake Borgeson Insider Trading Activity
Every SEC Form 4 transaction reported by Blake Borgeson, sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Is Blake Borgeson buying or selling?
Blake Borgeson reported 0 open-market buys ($0) and 65 sells ($10.3M) across 65 Form 4 filings at 1 company — a net selling position of $10.3M.
Source: SEC EDGAR Form 4
What stands out
- All 65 of Blake Borgeson's Form 4 filings are for one company, RECURSION PHARMACEUTICALS, INC. (RXRX).
- The most recent Form 4 was accepted on Oct 7, 2026 (11 days ago).
- In the last 12 months: no open-market purchases and 11 sales ($4.3M).
- The largest open-market sale in the last 12 months was $961.4K of RECURSION PHARMACEUTICALS, INC. (RXRX) on Dec 4, 2025. SEC ↗
Key Statistics (as of Oct 7, 2026)
Total Form 4 filings
65
SEC EDGAR
Companies
1
Buys (0)
$0
Sells (65)
$10.3M
Insider sentiment
Net sellingNet insider flow of $10.3M in net selling, filed between Nov 23, 2021 – Oct 7, 2026.
Companies Blake Borgeson files for
| # | Company | Form 4 filings |
|---|---|---|
| 1 | RXRXRECURSION PHARMACEUTICALS, INC. | 65 |
Recent Blake Borgeson transactions
| Date | Ticker | Role | Type | Shares | Value | Filing |
|---|---|---|---|---|---|---|
| Oct 7, 2026 | RXRX | Director | Sale | 50.0K | $242.0K | SEC ↗ |
| Sep 2, 2026 | RXRX | Director | Sale | 30.0K | $100.2K | SEC ↗ |
| Aug 6, 2026 | RXRX | Director | Sale | 30.0K | $97.5K | SEC ↗ |
| Jul 9, 2026 | RXRX | Director | Sale | 40.0K | $158.5K | SEC ↗ |
| Jun 4, 2026 | RXRX | Director | Sale | 30.0K | $110.4K | SEC ↗ |
| May 7, 2026 | RXRX | Director | Sale | 30.0K | $105.6K | SEC ↗ |
| Apr 8, 2026 | RXRX | Director | Sale | 30.0K | $93.0K | SEC ↗ |
| Mar 4, 2026 | RXRX | Director | Sale | 170.0K | $588.2K | SEC ↗ |
| Feb 6, 2026 | RXRX | Director | Sale | 220.0K | $924.0K | SEC ↗ |
| Jan 8, 2026 | RXRX | Director | Sale | 220.0K | $959.2K | SEC ↗ |
| Dec 4, 2025 | RXRX | Director | Sale | 220.0K | $961.4K | SEC ↗ |
| Nov 15, 2024 | RXRX | Director | Sale | 11.4K | $87.5K | SEC ↗ |
| Oct 31, 2024 | RXRX | Director | Sale | 11.4K | $76.9K | SEC ↗ |
| Oct 17, 2024 | RXRX | Director | Sale | 11.4K | $76.3K | SEC ↗ |
| Oct 3, 2024 | RXRX | Director | Sale | 11.4K | $71.1K | SEC ↗ |
| Sep 19, 2024 | RXRX | Director | Sale | 11.4K | $78.3K | SEC ↗ |
| Sep 5, 2024 | RXRX | Director | Sale | 11.4K | $71.7K | SEC ↗ |
| Aug 22, 2024 | RXRX | Director | Sale | 11.4K | $81.5K | SEC ↗ |
| Aug 8, 2024 | RXRX | Director | Sale | 11.4K | $78.1K | SEC ↗ |
| Jul 25, 2024 | RXRX | Director | Sale | 11.4K | $97.0K | SEC ↗ |
| Jul 11, 2024 | RXRX | Director | Sale | 11.4K | $83.7K | SEC ↗ |
| Jun 27, 2024 | RXRX | Director | Sale | 11.4K | $108.8K | SEC ↗ |
| Jun 13, 2024 | RXRX | Director | Sale | 11.4K | $96.8K | SEC ↗ |
| May 30, 2024 | RXRX | Director | Sale | 11.4K | $104.9K | SEC ↗ |
| May 16, 2024 | RXRX | Director | Sale | 20.1K | $202.9K | SEC ↗ |
Showing the 25 most recent filings of 65. Screen every filing.
Blake Borgeson insider trading FAQ
Is Blake Borgeson buying or selling?
Across 65 SEC Form 4 filings, Blake Borgeson reported 0 open-market purchases totaling $0 and 65 sales totaling $10.3M — a net selling position of $10.3M.
Which companies does Blake Borgeson file Form 4s for?
Blake Borgeson has reported insider transactions at 1 company, most often RECURSION PHARMACEUTICALS, INC. (RXRX).
How far back does Blake Borgeson's filing history go?
Trabud holds Blake Borgeson's SEC Form 4 filings from Nov 23, 2021 – Oct 7, 2026, sourced directly from SEC EDGAR.
Where does Trabud get Blake Borgeson's insider trading data?
Directly from SEC EDGAR Form 4 filings. Every transaction on this page is a real filing accepted by the SEC, updated as new filings arrive.
Related Content
Track Blake Borgeson and every other insider
Screen all SEC Form 4 filings by insider, company, transaction value, and role — or ask Trabud's AI agent in plain English.
Open the screener